TB4/TB-500 Subcutaneous Research Dosing Protocol
-
For research use only. Not medical advice.
Overview
TB4/TB-500 is a synthetic peptide that corresponds to the active region of thymosin beta-4, a naturally occurring protein involved in tissue repair, regeneration, angiogenesis, and cellular migration.
It is commonly used in research models focused on soft-tissue recovery, tendon/ligament healing, and systemic repair pathways.
The most common approach is once-daily subcutaneous dosing with gradual escalation.Daily Dosing Protocol
Standard Daily Range
500–1,000 mcg once daily
This matches the typical systemic dose range used in most animal and translational research models.
Titration Schedule
Weeks 1–2
500 mcg daily
Conservative starting point to assess tolerability.
Weeks 3–4
600 mcg daily
Weeks 5–8
750 mcg daily
This is the most common “working dose” for injury-repair protocols.
Upper-end daily dose used for intensive repair phases.
Timing
Once daily, at a consistent time.
Many researchers prefer evening dosing to align with recovery periods, but timing is flexible.
Cycle Length
Typical TB4/TB-500 research cycles:
4-8 weeks, depending on severity and type of tissue-repair model
4 weeks off before repeating
Some injury models include a “loading phase” (daily), then “maintenance phase” (2–3×/week), but daily remains the standard for systemic use
Common Research Notes
TB4/TB-500 distributes systemically and does not require localized injection.
Reported effects include improved mobility, reduced inflammation, accelerated soft-tissue recovery, and enhanced healing timelines.
Often stacked with BPC-157 for synergistic repair effects—TB-500 for systemic repair, BPC-157 for localized or gastrointestinal pathways.
Mild fatigue or warmth at the injection site may occur early in use.
